News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zymeworks and XOMA (US) LLC (XOMA) to Collaborate on Antibody Research Program


5/15/2009 11:07:03 AM

VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc., a privately held computational biotechnology company, today announced it has entered into a research agreement with California-based XOMA Ltd. (Nasdaq: XOMA, www.xoma.com) to optimize an undisclosed antibody using Zymeworks’ ZymeCAD™ suite of predictive protein engineering tools and XOMA’s innovative Targeted Affinity Enhancement™ (TAE™) technology for antibody mutagenesis and optimization. Financial terms are not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES